<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> and its precursor, <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>, are rapidly rising in incidence </plain></SENT>
<SENT sid="1" pm="."><plain>This review serves to highlight the role of pharmacologic, endoscopic, and surgical intervention in the management of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>, which requires acid suppression and endoscopic assessment </plain></SENT>
<SENT sid="2" pm="."><plain>Treatment with a <z:chebi fb="0" ids="49200">proton pump inhibitor</z:chebi> may decrease acid exposure and delay the progression to <z:mpath ids='MPATH_589'>dysplasia</z:mpath> </plain></SENT>
<SENT sid="3" pm="."><plain>Patients who require aspirin for cardioprotection or other indications may also benefit in terms of a protective effect against the development of <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>However, without other indications, aspirin is not indicated solely to prevent <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>A careful endoscopic examination should include assessment of any visible lesions in a Barrett's segment </plain></SENT>
<SENT sid="6" pm="."><plain>An expert gastrointestinal pathologist should confirm <z:hpo ids='HP_0002664'>neoplasia</z:hpo> in the setting of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>For those patients with high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> or intramucosal <z:mp ids='MP_0002038'>carcinoma</z:mp>, careful consideration of endoscopic therapy or surgical therapy must be given </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> visible lesions in the setting of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> should be targeted with focal endoscopic mucosal resection for both accurate histopathologic diagnosis and treatment </plain></SENT>
<SENT sid="9" pm="."><plain>The remainder of the Barrett's epithelium should be eradicated to address <z:hpo ids='HP_0000001'>all</z:hpo> synchronous and metachronous lesions </plain></SENT>
<SENT sid="10" pm="."><plain>This may be done by tissue acquiring or nontissue acquiring means </plain></SENT>
<SENT sid="11" pm="."><plain>Radiofrequency ablation has a positive benefit-risk profile for flat <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>At this time, endoscopic therapy is not indicated for nondysplastic <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="13" pm="."><plain>Esophagectomy is still reserved for selected cases with evidence of lymph node <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e>, unsuccessful endoscopic therapy, or with high-risk features of high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> or intramucosal <z:mp ids='MP_0002038'>carcinoma</z:mp> </plain></SENT>
</text></document>